-
1
-
-
70350148394
-
Understanding hiv-1 latency provides clues for the eradication of long-term reservoirs
-
Coiras M, Lopez-Huertas M, Perez-Olmeda M, Alcami J. 2009. Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat. Rev. Microbiol. 7:798-812.
-
(2009)
Nat. Rev. Microbiol.
, vol.7
, pp. 798-812
-
-
Coiras, M.1
Lopez-Huertas, M.2
Perez-Olmeda, M.3
Alcami, J.4
-
2
-
-
0036846898
-
New anti-hiv agents and targets
-
De Clercq. 2002. New anti-HIV agents and targets. Med. Res. Rev. 22: 531-565.
-
(2002)
Med. Res. Rev.
, vol.22
, pp. 531-565
-
-
De Clercq1
-
4
-
-
38649136321
-
Virological determinants of success after structured treatment interruptions of antiretrovirals in acute hiv-1 infection
-
Lewin SR, Murray J, Solomon A, Wightman F, Cameron PU, Purcell DJ, Zaunders JJ, Grey P, Bloch M, Smith D, Cooper DA, Kelleher AD. 2008. Virological determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection. J. Acquir. Immune Defic. Syndr. 47:140-147.
-
(2008)
J. Acquir. Immune Defic. Syndr.
, vol.47
, pp. 140-147
-
-
Lewin, S.R.1
Murray, J.2
Solomon, A.3
Wightman, F.4
Cameron, P.U.5
Purcell, D.J.6
Zaunders, J.J.7
Grey, P.8
Bloch, M.9
Smith, D.10
Cooper, D.A.11
Kelleher, A.D.12
-
5
-
-
3543125970
-
A long-term latent reservoir for hiv-1: Discovery and clinical implications
-
Siliciano JD, Siliciano RF. 2004. A long-term latent reservoir for HIV-1: discovery and clinical implications. J. Antimicrob. Chemother. 54:6-9.
-
(2004)
J. Antimicrob. Chemother.
, vol.54
, pp. 6-9
-
-
Siliciano, J.D.1
Siliciano, R.F.2
-
6
-
-
1842613542
-
Hiv-1 dynamics in vivo: Implications for therapy
-
Simon V, Ho DD. 2003. HIV-1 dynamics in vivo: implications for therapy. Nat. Rev. Microbiol. 1:181-190.
-
(2003)
Nat. Rev. Microbiol.
, vol.1
, pp. 181-190
-
-
Simon, V.1
Ho, D.D.2
-
7
-
-
0043069555
-
Toxicity of antiretroviral therapy and implications for drug development
-
Carr. 2003. Toxicity of antiretroviral therapy and implications for drug development. Nat. Rev. Drug Discov. 2:624-634.
-
(2003)
Nat. Rev. Drug Discov.
, vol.2
, pp. 624-634
-
-
Carr1
-
8
-
-
0242539778
-
New patterns of hiv-1 resistance during haart
-
Fumero E, Podzamczer D. 2003. New patterns of HIV-1 resistance during HAART. Clin. Microbiol. Infect. 9:1077-1084.
-
(2003)
Clin. Microbiol. Infect.
, vol.9
, pp. 1077-1084
-
-
Fumero, E.1
Podzamczer, D.2
-
9
-
-
33746802081
-
Differential impact of combination antiretroviral therapy in preventing kaposi's sarcoma with and without visceral involvement
-
Grabar S, Abraham B, Mahamat A, Del Giudice P, Rosenthal E, Costagliola D. 2006. Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement. J. Clin. Oncol. 24:3408-3414.
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 3408-3414
-
-
Grabar, S.1
Abraham, B.2
Mahamat, A.3
Del Giudice, P.4
Rosenthal, E.5
Costagliola, D.6
-
11
-
-
0037043652
-
Antiretroviral-drug resistance among patients recently infected with hiv
-
Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:385-394.
-
(2002)
N. Engl. J. Med.
, vol.347
, pp. 385-394
-
-
Little, S.J.1
Holte, S.2
Routy, J.P.3
Daar, E.S.4
Markowitz, M.5
Collier, A.C.6
Koup, R.A.7
Mellors, J.W.8
Connick, E.9
Conway, B.10
Kilby, M.11
Wang, L.12
Whitcomb, J.M.13
Hellmann, N.S.14
Richman, D.D.15
-
12
-
-
0032558813
-
Antiretroviral drugs and the central nervous system
-
Enting RH, Hoetelmans R, Lange JM, Burger DM, Beijnen JH, Portegies P. 1998. Antiretroviral drugs and the central nervous system. AIDS 12:1941-1955.
-
(1998)
AIDS
, vol.12
, pp. 1941-1955
-
-
Enting, R.H.1
Hoetelmans, R.2
Lange, J.M.3
Burger, D.M.4
Beijnen, J.H.5
Portegies, P.6
-
13
-
-
21344455519
-
Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus
-
Kramer-Hammerle S, Rothenaigner I, Wolff H, Bell JE, Brack-Werner R. 2005. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res. 111:194-213.
-
(2005)
Virus Res.
, vol.111
, pp. 194-213
-
-
Kramer-Hammerle, S.1
Rothenaigner, I.2
Wolff, H.3
Bell, J.E.4
Brack-Werner, R.5
-
15
-
-
33746902777
-
Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients
-
Langford D, Marquie-Beck J, de Almeida S, Lazzaretto D, Letendre S, Grant I, McCutchan JA, Masliah E, Ellis RJ. 2006. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. J. Neurovirol. 12:100-107.
-
(2006)
J. Neurovirol.
, vol.12
, pp. 100-107
-
-
Langford, D.1
Marquie-Beck, J.2
De Almeida, S.3
Lazzaretto, D.4
Letendre, S.5
Grant, I.6
McCutchan, J.A.7
Masliah, E.8
Ellis, R.J.9
-
16
-
-
33747335917
-
Influence of highly active antiretroviral therapy on persistence of hiv in the central nervous system
-
Nath A, Sacktor N. 2006. Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr. Opin. Neurol. 19:358-361.
-
(2006)
Curr. Opin. Neurol.
, vol.19
, pp. 358-361
-
-
Nath, A.1
Sacktor, N.2
-
17
-
-
84878784823
-
Targeting the glutamatergic system for the treatment of hiv-associated neurocognitive disorders
-
Potter MC, Figuera-Losada M, Rojas C, Slusher BS. 2013. Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders. J. Neuroimmune Pharmacol. 8:594-607.
-
(2013)
J. Neuroimmune Pharmacol.
, vol.8
, pp. 594-607
-
-
Potter, M.C.1
Figuera-Losada, M.2
Rojas, C.3
Slusher, B.S.4
-
18
-
-
0036948147
-
The epidemiology of human immunodeficiency virusassociated neurological disease in the era of highly active antiretroviral therapy
-
Sacktor. 2002. The epidemiology of human immunodeficiency virusassociated neurological disease in the era of highly active antiretroviral therapy. J. Neurovirol. 8:115-121.
-
(2002)
J. Neurovirol.
, vol.8
, pp. 115-121
-
-
Sacktor1
-
19
-
-
84856452536
-
Hiv-associated neurological disorders: A guide to pharmacotherapy
-
Tan IL, McArthur JC. 2012. HIV-associated neurological disorders: a guide to pharmacotherapy. CNS Drugs 26:123-134.
-
(2012)
CNS Drugs
, vol.26
, pp. 123-134
-
-
Tan, I.L.1
McArthur, J.C.2
-
20
-
-
4444235837
-
Independent evolution of human immunodeficiency virus (hiv) drug resistance mutations in diverse areas of the brain in hivinfected patients, with and without dementia, on antiretroviral treatment
-
Smit TK, Brew BJ, Tourtellotte W, Morgello S, Gelman BB, Saksena NK. 2004. Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIVinfected patients, with and without dementia, on antiretroviral treatment. J. Virol. 78:10133-10148.
-
(2004)
J. Virol.
, vol.78
, pp. 10133-10148
-
-
Smit, T.K.1
Brew, B.J.2
Tourtellotte, W.3
Morgello, S.4
Gelman, B.B.5
Saksena, N.K.6
-
21
-
-
0034671498
-
Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid hiv rna in hiv-1-infected patients receiving antiretroviral therapy
-
Gisolf EH, Van Praaq R, Jurriaans S, Portegies P, Goudsmit J, Danner SA, Lange JM, Prins JM. 2000. Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 25:426-433.
-
(2000)
J. Acquir. Immune Defic. Syndr.
, vol.25
, pp. 426-433
-
-
Gisolf, E.H.1
Van Praaq, R.2
Jurriaans, S.3
Portegies, P.4
Goudsmit, J.5
Danner, S.A.6
Lange, J.M.7
Prins, J.M.8
-
23
-
-
0036800561
-
Hiv-related neuropathology, 1985 to 1999: Rising prevalence of hiv encephalopathy in the era of highly active antiretroviral therapy
-
Neuenburg JK, Brodt HR, Herndier BG, Bickel M, Bacchetti P, Price RW, Grant RM, Schlote W. 2002. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 31:171-177.
-
(2002)
J. Acquir. Immune Defic. Syndr.
, vol.31
, pp. 171-177
-
-
Neuenburg, J.K.1
Brodt, H.R.2
Herndier, B.G.3
Bickel, M.4
Bacchetti, P.5
Price, R.W.6
Grant, R.M.7
Schlote, W.8
-
24
-
-
0032122490
-
Cellular and anatomical reservoirs of hiv-1 in patients receiving potent antiretroviral combination therapy
-
Schrager LK, D'Souza MP. 1998. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 280:67-71.
-
(1998)
JAMA
, vol.280
, pp. 67-71
-
-
Schrager, L.K.1
D'Souza, M.P.2
-
25
-
-
0035912198
-
Pathways to neuronal injury and apoptosis in hiv-associated dementia
-
Kaul M, Garden G, Lipton SA. 2001. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410:988-994.
-
(2001)
Nature
, vol.410
, pp. 988-994
-
-
Kaul, M.1
Garden, G.2
Lipton, S.A.3
-
26
-
-
0032539842
-
Potent hiv protease inhibitors incorporating high-affinity p2-ligands and (r)-(hydroxyethylamino)sulfonamide isostere
-
Ghosh AK, Krishnan K, Walters DE, Cho W, Cho H, Koo Y, Trevino J, Holland L, Buthod J. 1998. Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere. Bioorg. Med. Chem. Lett. 8:687-690.
-
(1998)
Bioorg. Med. Chem. Lett.
, vol.8
, pp. 687-690
-
-
Ghosh, A.K.1
Krishnan, K.2
Walters, D.E.3
Cho, W.4
Cho, H.5
Koo, Y.6
Trevino, J.7
Holland, L.8
Buthod, J.9
-
27
-
-
0032554691
-
Structure based design: Novel spirocyclic ethers as nonpeptidal p2-ligands for hiv protease inhibitors
-
Ghosh AK, Cho W, Walters DE, Krishnan K, Hussain KA, Koo Y, Cho H, Rudall C, Holland L, Buthod J. 1998. Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors. Bioorg. Med. Chem. Lett. 8:979-982.
-
(1998)
Bioorg. Med. Chem. Lett.
, vol.8
, pp. 979-982
-
-
Ghosh, A.K.1
Cho, W.2
Walters, D.E.3
Krishnan, K.4
Hussain, K.A.5
Koo, Y.6
Cho, H.7
Rudall, C.8
Holland, L.9
Buthod, J.10
-
28
-
-
10744226241
-
Novel bis-tetrahydrofuranylurethane- containing nonpeptidic protease inhibitor (pi) uic- 94017 (tmc114) with potent activity against multi-pi-resistant human immunodeficiency virus in vitro
-
Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Devasamudram T, Kincaid JF, Boross P, Wang YF, Tie Y, Volarath P, Gaddis L, Harrison RW, Weber IT, Ghosh AK, Mitsuya H. 2003. Novel bis-tetrahydrofuranylurethane- containing nonpeptidic protease inhibitor (PI) UIC- 94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 47: 3123-3129.
-
(2003)
Antimicrob. Agents Chemother.
, vol.47
, pp. 3123-3129
-
-
Koh, Y.1
Nakata, H.2
Maeda, K.3
Ogata, H.4
Bilcer, G.5
Devasamudram, T.6
Kincaid, J.F.7
Boross, P.8
Wang, Y.F.9
Tie, Y.10
Volarath, P.11
Gaddis, L.12
Harrison, R.W.13
Weber, I.T.14
Ghosh, A.K.15
Mitsuya, H.16
-
29
-
-
0028823560
-
Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells
-
Shirasaka T, Chokekijchai S, Yamada A, Gosselin G, Imbach JL, Mitsuya H. 1995. Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells. Antimicrob. Agents Chemother. 39: 2555-2559.
-
(1995)
Antimicrob. Agents Chemother.
, vol.39
, pp. 2555-2559
-
-
Shirasaka, T.1
Chokekijchai, S.2
Yamada, A.3
Gosselin, G.4
Imbach, J.L.5
Mitsuya, H.6
-
30
-
-
8644220502
-
Stereoselective photochemical 1,3-dioxolane addition to 5-alkoxymethyl-2(5h)-furanone: Synthesis of bis-tetrahydrofuranyl ligand for hiv protease inhibitor uic-94017 (tmc-114)
-
Ghosh AK, Leshchenko S, Noetzel M. 2004. Stereoselective photochemical 1,3-dioxolane addition to 5-alkoxymethyl-2(5H)-furanone: synthesis of bis-tetrahydrofuranyl ligand for HIV protease inhibitor UIC-94017 (TMC-114). J. Org. Chem. 69:7822-7829.
-
(2004)
J. Org. Chem.
, vol.69
, pp. 7822-7829
-
-
Ghosh, A.K.1
Leshchenko, S.2
Noetzel, M.3
-
31
-
-
34250169806
-
A novel bis-tetrahydrofuranylurethanecontaining nonpeptidic protease inhibitor (pi), grl-98065, is potent against multiple-pi-resistant human immunodeficiency virus in vitro
-
Amano M, Koh Y, Das D, Li J, Leschenko S, Wang YF, Boross PI, Weber IT, Ghosh AK, Mitsuya H. 2007. A novel bis-tetrahydrofuranylurethanecontaining nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 51:2143-2155.
-
(2007)
Antimicrob. Agents Chemother.
, vol.51
, pp. 2143-2155
-
-
Amano, M.1
Koh, Y.2
Das, D.3
Li, J.4
Leschenko, S.5
Wang, Y.F.6
Boross, P.I.7
Weber, I.T.8
Ghosh, A.K.9
Mitsuya, H.10
-
32
-
-
79953204965
-
Novel hiv-1 protease inhibitors (pis) containing a bicyclic p2 functional moiety, tetrahydropyranotetrahydrofuran, that are potent against multi-pi-resistant hiv-1 variants
-
Ide K, Aoki M, Amano M, Koh Y, Yedidi RS, Das D, Leschenko S, Chapsal B, Ghosh AK, Mitsuya H. 2011. Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyranotetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variants. Antimicrob. Agents Chemother. 55:1717-1727.
-
(2011)
Antimicrob. Agents Chemother.
, vol.55
, pp. 1717-1727
-
-
Ide, K.1
Aoki, M.2
Amano, M.3
Koh, Y.4
Yedidi, R.S.5
Das, D.6
Leschenko, S.7
Chapsal, B.8
Ghosh, A.K.9
Mitsuya, H.10
-
33
-
-
77955348909
-
Novel protease inhibitors (pis) containing macrocyclic components and 3(r),3a(s),6a(r)-bis-tetrahydrofuranylurethane that are potent against multi-pi-resistant hiv-1 variants in vitro
-
Tojo Y, Koh Y, Amano M, Aoki M, Das D, Kulkarni S, Anderson DD, Ghosh AK, Mitsuya H. 2010. Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro. Antimicrob. Agents Chemother. 54:3460-3470.
-
(2010)
Antimicrob. Agents Chemother.
, vol.54
, pp. 3460-3470
-
-
Tojo, Y.1
Koh, Y.2
Amano, M.3
Aoki, M.4
Das, D.5
Kulkarni, S.6
Anderson, D.D.7
Ghosh, A.K.8
Mitsuya, H.9
-
34
-
-
60949110463
-
A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes
-
Nakagawa S, Deli MA, Kawaguchi H, Shimizudani T, Shimono T, Kittel A, Tanaka K, Niwa M. 2009. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem. Int. 54:253-263.
-
(2009)
Neurochem. Int.
, vol.54
, pp. 253-263
-
-
Nakagawa, S.1
Deli, M.A.2
Kawaguchi, H.3
Shimizudani, T.4
Shimono, T.5
Kittel, A.6
Tanaka, K.7
Niwa, M.8
-
35
-
-
0036145503
-
A potent human immunodeficiency virus type 1 protease inhibitor, uic- 94003 (tmc-126), and selection of a novel (a28s) mutation in the protease active site
-
Yoshimura K, Kato R, Kavlick MF, Nguyen A, Maroun V, Maeda K, Hussain KA, Ghosh AK, Gulnik SV, Erickson JW, Mitsuya H. 2002. A potent human immunodeficiency virus type 1 protease inhibitor, UIC- 94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. J. Virol. 76:1349-1358.
-
(2002)
J. Virol.
, vol.76
, pp. 1349-1358
-
-
Yoshimura, K.1
Kato, R.2
Kavlick, M.F.3
Nguyen, A.4
Maroun, V.5
Maeda, K.6
Hussain, K.A.7
Ghosh, A.K.8
Gulnik, S.V.9
Erickson, J.W.10
Mitsuya, H.11
-
36
-
-
78049524808
-
In vitro selection of highly darunavir-resistant and replication- competent hiv-1 variants by using a mixture of clinical hiv-1 isolates resistant to multiple conventional protease inhibitors
-
Koh Y, Amano M, Towata T, Danish M, Leshchenko-Yashchuk S, Das D, Nakayama M, Tojo Y, Ghosh AK, Mitsuya H. 2010. In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors. J. Virol. 84:11961-11969.
-
(2010)
J. Virol.
, vol.84
, pp. 11961-11969
-
-
Koh, Y.1
Amano, M.2
Towata, T.3
Danish, M.4
Leshchenko-Yashchuk, S.5
Das, D.6
Nakayama, M.7
Tojo, Y.8
Ghosh, A.K.9
Mitsuya, H.10
-
37
-
-
84873384211
-
A convenient medical-microbial method for developing fluorinated pharmaceuticals
-
Bright TV, Dalton F, Elder VL, Murphy CD, O'Connor NK, Sandford G. 2013. A convenient medical-microbial method for developing fluorinated pharmaceuticals. Org. Biomol. Chem. 11:1135-1142.
-
(2013)
Org. Biomol. Chem.
, vol.11
, pp. 1135-1142
-
-
Bright, T.V.1
Dalton, F.2
Elder, V.L.3
Murphy, C.D.4
O'Connor, N.K.5
Sandford, G.6
-
38
-
-
34248664984
-
Adsorption of drugs onto aph responsive poly(n,n dimethyl aminoethyl methacrylate) grafted anion-exchange membrane in vitro
-
Karppi J, Akerman S, Akerman K, Sundell A, Nyyssonen K, Penttila I. 2007. Adsorption of drugs onto apH responsive poly(N,N dimethyl aminoethyl methacrylate) grafted anion-exchange membrane in vitro. Int. J. Pharm. 338:7-14.
-
(2007)
Int. J. Pharm.
, vol.338
, pp. 7-14
-
-
Karppi, J.1
Akerman, S.2
Akerman, K.3
Sundell, A.4
Nyyssonen, K.5
Penttila, I.6
-
39
-
-
50549096031
-
Fluorinated nucleosides: Synthesis and biological implication
-
Liu P, Sharon A, Chu CK. 2008. Fluorinated nucleosides: synthesis and biological implication. J. Fluor. Chem. 129:743-766.
-
(2008)
J. Fluor. Chem.
, vol.129
, pp. 743-766
-
-
Liu, P.1
Sharon, A.2
Chu, C.K.3
-
40
-
-
84877297802
-
On the solubility and lipophilicity of metallacarborane pharmacophores
-
Rak J, Dejlová B, Lampová H, Kaplánek R, Mate?jíc?ek P, Cígler P, Král V. 2013. On the solubility and lipophilicity of metallacarborane pharmacophores. Mol. Pharm. 10:1751-1759.
-
(2013)
Mol. Pharm.
, vol.10
, pp. 1751-1759
-
-
Rak, J.1
Dejlová, B.2
Lampová, H.3
Kaplánek, R.4
Matejícek, P.5
Cígler, P.6
Král, V.7
-
41
-
-
34748815589
-
Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells
-
Nakagawa S, Deli MA, Nakao S, Honda M, Hayashi K, Nakaoke R, Kataoka Y, Niwa M. 2007. Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells. Cell. Mol. Neurobiol. 27:687-694.
-
(2007)
Cell. Mol. Neurobiol.
, vol.27
, pp. 687-694
-
-
Nakagawa, S.1
Deli, M.A.2
Nakao, S.3
Honda, M.4
Hayashi, K.5
Nakaoke, R.6
Kataoka, Y.7
Niwa, M.8
-
42
-
-
34547645047
-
Modelling of the blood brain barrier in drug discovery and development
-
Cecchelli R, Berezowski V, Lundquist S, Culot M, Renftel M, Dehouck MP, Fenart L. 2007. Modelling of the blood brain barrier in drug discovery and development. Nat. Rev. Drug Discov. 6:650-661.
-
(2007)
Nat. Rev. Drug Discov.
, vol.6
, pp. 650-661
-
-
Cecchelli, R.1
Berezowski, V.2
Lundquist, S.3
Culot, M.4
Renftel, M.5
Dehouck, M.P.6
Fenart, L.7
-
43
-
-
33845968810
-
Screening and selecting for optimized antiretroviral drugs: Rising to the challenge of drug resistance
-
de Bethune MP, Hertogs K. 2006. Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance. Curr. Med. Res. Opin. 22:2603-2612.
-
(2006)
Curr. Med. Res. Opin.
, vol.22
, pp. 2603-2612
-
-
De Bethune, M.P.1
Hertogs, K.2
-
44
-
-
84873382351
-
Dynamics of cellular hiv-1 dna levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the monet trial
-
Geretti AM, Arribas J, Lathouwers E, Foster GM, Yakoob R, Kinloch S, Hill A, van Delft Y, Moecklinghoff C. 2013. Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial. HIV Clin. Trials 14:45-50.
-
(2013)
HIV Clin. Trials
, vol.14
, pp. 45-50
-
-
Geretti, A.M.1
Arribas, J.2
Lathouwers, E.3
Foster, G.M.4
Yakoob, R.5
Kinloch, S.6
Hill, A.7
Van Delft, Y.8
Moecklinghoff, C.9
-
45
-
-
84870533547
-
Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared to lopinavir/ritonavir in hiv-1-infected treatment-naive patients in the artemis trial
-
Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Lathouwers E, Lefebvre E, Opsomer M, Van de Casteele T, Tomaka F. 2013. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared to lopinavir/ritonavir in HIV-1-infected treatment-naive patients in the ARTEMIS trial. HIV Med. 14:49-59.
-
(2013)
HIV Med.
, vol.14
, pp. 49-59
-
-
Orkin, C.1
DeJesus, E.2
Khanlou, H.3
Stoehr, A.4
Supparatpinyo, K.5
Lathouwers, E.6
Lefebvre, E.7
Opsomer, M.8
Van De Casteele, T.9
Tomaka, F.10
-
46
-
-
84860272506
-
Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/ r in treatment-experienced patients in titan
-
Banhegyi D, Katlama C, da Cunha CA, Schneider S, Rachlis A, Workman C, De Meyer S, Vandevoorde A, Van De Casteele T, Tomaka F. 2012. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/ r in treatment-experienced patients in TITAN. Curr. HIV Res. 10:171-181.
-
(2012)
Curr. HIV Res.
, vol.10
, pp. 171-181
-
-
Banhegyi, D.1
Katlama, C.2
Da Cunha, C.A.3
Schneider, S.4
Rachlis, A.5
Workman, C.6
De Meyer, S.7
Vandevoorde, A.8
Van De Casteele, T.9
Tomaka, F.10
-
47
-
-
78349254240
-
Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in hiv-1 protease inhibitors
-
Ghosh AK, Xu CX, Rao KV, Baldridge A, Agniswamy J, Wang YF, Weber IT, Aoki M, Miguel SG, Amano M, Mitsuya H. 2010. Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors. ChemMedChem 5:1850- 1854.
-
(2010)
ChemMedChem
, vol.5
, pp. 1850-1854
-
-
Ghosh, A.K.1
Xu, C.X.2
Rao, K.V.3
Baldridge, A.4
Agniswamy, J.5
Wang, Y.F.6
Weber, I.T.7
Aoki, M.8
Miguel, S.G.9
Amano, M.10
Mitsuya, H.11
-
48
-
-
35348960903
-
Potent inhibition of hiv-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization
-
Koh Y, Matsumi S, Das D, Amano M, Davis DA, Leschenko S, Baldridge A, Shioda T, Yarchoan R, Ghosh AK, Mitsuya H. 2007. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J. Biol. Chem. 282:28709-28720.
-
(2007)
J. Biol. Chem.
, vol.282
, pp. 28709-28720
-
-
Koh, Y.1
Matsumi, S.2
Das, D.3
Amano, M.4
Davis, D.A.5
Leschenko, S.6
Baldridge, A.7
Shioda, T.8
Yarchoan, R.9
Ghosh, A.K.10
Mitsuya, H.11
-
49
-
-
84864279941
-
Determinants of darunavir cerebrospinal fluid concentrations: Impact of once-daily dosing and pharmacogenetics
-
Calcagno A, Yilmaz A, Cusato J, Simiele M, Bertucci R, Siccardi M, Marinaro L, D'Avolio A, Di Perri G, Bonora S. 2012. Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. AIDS 26:1529-1533.
-
(2012)
AIDS
, vol.26
, pp. 1529-1533
-
-
Calcagno, A.1
Yilmaz, A.2
Cusato, J.3
Simiele, M.4
Bertucci, R.5
Siccardi, M.6
Marinaro, L.7
D'Avolio, A.8
Di Perri, G.9
Bonora, S.10
-
50
-
-
84876207904
-
Grl-0519, a novel oxatricyclic ligand-containing nonpeptidic hiv-1 protease inhibitor (pi), potently suppresses replication of a wide spectrum of multi-pi-resistant variants in vitro
-
Amano M, Tojo Y, Salcedo-Gomez PM, Campbell JR, Das D, Aoki M, Xu CX, Rao KV, Ghosh AK, Mitsuya H. 2013. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant variants in vitro. Antimicrob. Agents Chemother. 57:2036-2046.
-
(2013)
Antimicrob. Agents Chemother.
, vol.57
, pp. 2036-2046
-
-
Amano, M.1
Tojo, Y.2
Salcedo-Gomez, P.M.3
Campbell, J.R.4
Das, D.5
Aoki, M.6
Xu, C.X.7
Rao, K.V.8
Ghosh, A.K.9
Mitsuya, H.10
-
51
-
-
55249120981
-
Minority human immunodeficiency virus type 1 variants in antiretroviral- naive persons with reverse transcriptase codon 215 revertant mutations
-
Mitsuya Y, Varghese V, Wang C, Liu TF, Holmes SP, Jayakumar P, Gharizadeh B, Ronaghi M, Klein D, Fessel WJ, Shafer RW. 2008. Minority human immunodeficiency virus type 1 variants in antiretroviral- naive persons with reverse transcriptase codon 215 revertant mutations. J. Virol. 82:10747-10755.
-
(2008)
J. Virol.
, vol.82
, pp. 10747-10755
-
-
Mitsuya, Y.1
Varghese, V.2
Wang, C.3
Liu, T.F.4
Holmes, S.P.5
Jayakumar, P.6
Gharizadeh, B.7
Ronaghi, M.8
Klein, D.9
Fessel, W.J.10
Shafer, R.W.11
-
52
-
-
49849094738
-
Physiochemical drug properties associated with in vivo toxicological outcomes
-
Hughes JD, Blagg J, Price DA, Bailey S, Decrescenzo GA, Devraj RV, Ellsworth E, Fobian YM, Gibbs ME, Gilles RW, Greene N, Huang E, Krieger-Burke T, Loesel J, Wager T, Whiteley L, Zhang Y. 2008. Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg. Med. Chem. Lett. 18:4872-4875.
-
(2008)
Bioorg. Med. Chem. Lett.
, vol.18
, pp. 4872-4875
-
-
Hughes, J.D.1
Blagg, J.2
Price, D.A.3
Bailey, S.4
Decrescenzo, G.A.5
Devraj, R.V.6
Ellsworth, E.7
Fobian, Y.M.8
Gibbs, M.E.9
Gilles, R.W.10
Greene, N.11
Huang, E.12
Krieger-Burke, T.13
Loesel, J.14
Wager, T.15
Whiteley, L.16
Zhang, Y.17
-
53
-
-
67649962669
-
Rapid assessment of a novel series of selective cb2 agonists using parallel synthesis protocols: A lipophilic efficiency (lipe) analysis
-
Ryckmans T, Edwards MP, Horne VA, Correia AM, Owen DR, Thompson LR, Tran I, Tutt MF, Young T. 2009. Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: a lipophilic efficiency (LipE) analysis. Bioorg. Med. Chem. Lett. 19:4406-4409.
-
(2009)
Bioorg. Med. Chem. Lett.
, vol.19
, pp. 4406-4409
-
-
Ryckmans, T.1
Edwards, M.P.2
Horne, V.A.3
Correia, A.M.4
Owen, D.R.5
Thompson, L.R.6
Tran, I.7
Tutt, M.F.8
Young, T.9
-
54
-
-
65449179589
-
Defining optimum lipophilicity and molecular weight ranges for drug candidates-molecular weight dependent lower log d limits based on permeability
-
Waring MJ. 2009. Defining optimum lipophilicity and molecular weight ranges for drug candidates-molecular weight dependent lower log D limits based on permeability. Bioorg. Med. Chem. Lett. 19:2844-2851.
-
(2009)
Bioorg. Med. Chem. Lett.
, vol.19
, pp. 2844-2851
-
-
Waring, M.J.1
-
55
-
-
19444368758
-
-
Organisation for Economic Cooperation and Development. Test no. 107. Organisation for Economic Cooperation and Development, Paris, France. doi:10.1787/20745753
-
Organisation for Economic Cooperation and Development. 1995. OECD guidelines for the testing of chemicals, section 1: physical-chemical properties. Test no. 107. Organisation for Economic Cooperation and Development, Paris, France. doi:10.1787/20745753.
-
(1995)
OECD Guidelines for the Testing of Chemicals, Section 1: Physical-Chemical Properties
-
-
|